Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Shareholder Meeting (November 2005)
19 slides from Pyc Therapeutics's shareholder meeting presentation, Nov 25, 2005
Slide 1: AGM Presentation, November 2005
Aki von Roy Chairman AGM Stewart Washer CEO November, 2005
Slide 2: Drug candidates already yielded
as already yielded drug candidates betes. PHYLOGICA OW A ees
Slide 3: Company - therapeutic peptides
mpany - therapeutic peptides n Institute for Child Health d Fox Chase Cancer Center (USA) n board and management team xpert biotech analysts HYLOGICA
Slide 4: Phylogica Limited
ica Limited in peptide drug discovery. ~ proprietary drug discovery technology MHYLOGICA
Slide 5: History and strategic partnerships
istory rategic partnerships YLOGIC S
Slide 6: Board and Management
rd and Management of experience and expertise Aki) von Roy —Chairman ormer President of Bristol-Myers Squibb, Europe : : tional experience in pharmaceutical companies, G and Bristol-Myers Squibb ‘operty : ecord in building profitable biotech companies Ha ard Universities. PHYLOGIC
Slide 7: Management experience
experience in the pharmaceutical and stry : business development, IP management and ry knowledge and expertise i ness management and science HYLOGICA VO Bee
Slide 8: Phylogica Value
ogica Value avering new drug candidates ig. a pipeline of.drug candidates in HYLOGICA DO Ay aoe
Slide 9: Brain damage in Stroke
brain damage in Stroke Significant Cause of Long Term Damage Impairment of function (penumbra) Structural lesion jj Minutes Days & weeks HYLOGICA VO Bee
Slide 10: SP34...SP-36 peptide
o_o SP34...SP-36 SP 71 . 4uM peptide OGICA
Slide 11: ODM EE
ODM EE —— —————T ————— anonsmapcnntree seinen — pudoaspursir Hin
Slide 12: SP36 and SP74 peptides
ut SP36 USP. SP74 TIJIP. YLOGICA
Slide 13: Following global cerebral ischaemia
id n following global cerebral ischaemia aghibitory Phylomers (in vivo) ia: no treatment HYLOGICA
Slide 14: Phylomer libraries: lineages included
Eukarya ste ey, Animals alopliles Stime moids Bacteria oye pocsuria Cranobacterts Fungi Plants Fhermonrotens ‘oma Green nonsulfar bacteria Entamoebae Citiates Flagellares Trichomonads Microsporidia Aggaedtione Diplomonads Lineages included in | Phyfomer © Librari PHYLOGIC D4 :
Slide 15: Intellectual Property
ual Property d patent portfolio tions undergoing national ae (PCT) and 2 provisional atent applications filed =. HYLOGICA
Slide 16: Disease targets and collaborators
ACUTE TRAUMA : 3 Collaborators PSORIASIS he ‘ NMRI STROKE Uni of Melbourne Garvin Institute UWA * _ ALLERGIES COLITIS : . RHEUMATOID : ARTHRITIS IRRITABLE BOWEL SYNDROME ese targets are suitab! : multiple disease DHYLOGICA
Slide 17: Business Model
ess Model. value ha ique peptide drug discovery y (Phylome d drug candidates with preclinical ata packages (stroke, asthma, RA and diabetes) s being partnered for target. co-development of new drug lead! ns and grants are.importan technology into new diseast HYLOGICA OW A ees
Slide 18: Biotech Comparators
tech Comparators. value. ar ples where biotechnology ilar drug discovery platforms chnologies. owns.a library for nd is valued at-around £360m | HYLOGICA OW A ees
Slide 19: Phylogica
HYLOGICA OW A ees